Corneal neovascularization and the utility of topical VEGF inhibition: Ranibizumab (Lucentis) Vs bevacizumab (Avastin)

Ocular Surface

Volumn 10, Issue 2, 2012, Pages 67-83

  Stevenson, William ^a   Cheng, Sheng Fu ^a   Dastjerdi, Mohammad H ^a   Ferrari, Giulio ^b   Dana, Reza ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b IRCCS FONDAZIONE BIETTI   (Italy)

Author keywords

Angiogenesis; Bevacizumab; Cornea; Corneal angiogenic privilege; Hemangiogenesis; Lymphangiogenesis; Neovascularization; Ranibizumab; Vascular endothelial growth factor; VEGF

Indexed keywords

ANGIOPOIETIN; ANGIOSTATIN; BEVACIZUMAB; CD36 ANTIGEN; COLLAGEN DERIVATIVE; CORTICOSTEROID; FIBROBLAST GROWTH FACTOR; MATRIX METALLOPROTEINASE; NONSTEROID ANTIINFLAMMATORY AGENT; PIGMENT EPITHELIUM DERIVED FACTOR; PLATELET DERIVED GROWTH FACTOR; RANIBIZUMAB; THROMBOSPONDIN; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

ADULT; AGED; ANGIOGENESIS; ARTERIOLAR HEMORRHAGE; ARTICLE; BLEEDING; BLINDNESS; CASE REPORT; CORNEA DISEASE; CORNEA NEOVASCULARIZATION; CORNEA PERFORATION; CORNEA THICKNESS; CORNEA TRANSPLANTATION; CORNEA ULCER; CORNEAL EPITHELIOPATHY; CORTICOSTEROID THERAPY; DIATHERMY; DRUG EFFICACY; DRUG SAFETY; EYE INJURY; EYE SURGERY; FINE NEEDLE DIATHERMY; HUMAN; LASER COAGULATION; OCULAR SURFACE RECONSTRUCTION; PATHOGENESIS; PHOTODYNAMIC THERAPY; PROSPECTIVE STUDY; SIDE EFFECT; SIGNAL TRANSDUCTION; VISUAL ACUITY; VISUAL IMPAIRMENT; WOUND HEALING;

EID: 85027943379     PISSN: 15420124     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jtos.2012.01.005     Document Type: Review

References (263)

1. Beebe DC. Maintaining transparency: a review of the developmental physiology and pathophysiology of two avascular tissues. Semin Cell Dev Biol 2008;19:125-33 (Pubitemid 351258368)
2. Azar DT. Corneal angiogenic privilege: angiogenic and antiangiogenic factors in corneal avascularity, vasculogenesis, and wound healing (American Ophthalmological Society thesis). Trans Am Ophthalmol Soc 2006;104:264-302 (Pubitemid 46495064)
3. Gupta D, Illingworth C. Treatments for corneal neovascularization: a review. Cornea 2011;30:927-38
4. Carmeliet P, Jain RK. Molecular mechanisms and clinical applications of angiogenesis. Nature 2011;473(7347):298-307
5. Avery RL, Pieramici DJ, Rabena MD, et al. Intravitreal bevacizumab (Avastin) for neovascular age related macular degeneration. Ophthalmology 2006;113:363-72
6. Avery RL, Pearlman J, Pieramici DJ, et al. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology 2006;113:1695.e1-15
7. Bock F, König Y, Dietrich T, et al. Inhibition of angiogenesis in the anterior chamber of the eye. Ophthalmologe 2007;104:336-44
8. Ranpura V, Hapani S, Wu S. Treatment-related mortality with bevacizumab in cancer patients: a meta-analysis. JAMA 2011;305:487-94
9. WHO releases the new global estimates on visual impairment. World Health Organization Web site. 2010. Available at: http://www.who.int/ blindness/en. Accessed August 2, 2011
10. Whitcher JP, Srinivasan M, Upadhyay MP. Corneal blindness: a global perspective. Bull World Health Organ:214-21, http://www.who.int/ bulletin/archives/79%283%29214.pdf, 2001;79Accessed August 2, 2011.
11. Program for the prevention of blindness and deafness: data available on blindness. World Health Organization Web site. 2006. Available at: http://www.who.int/blindness/publications/global-data.pdf. Accessed August 2, 2011
12. Lee P, Wang CC, Adamis AP. Ocular neovascularization: an epidemiologic review. Surv Ophthalmol 1998;43:245-69 (Pubitemid 28558273)
13. Epstein RJ, Stulting RD, Hendricks RL, Harris DM. Corneal neovascularization. Pathogenesis and inhibition. Cornea 1987;6:250-7 (Pubitemid 18005952)
14. Report of the global scientific meeting on future approaches to trachoma control. Geneva, 17-20 June 1996. World Health Organization. 1997 Available at: http://whqlibdoc.who.int/hq/1996/WHO- PBL-96.56.pdf. Accessed August 2, 2011
15. Solomon AW, Zondervan M, Kuper H, et al. Trachoma control: a guide for programme managers. World Health Organization. Available at: http://www.who.int/blindness/publications/tcm%20who-pbd-get-06- 1.pdf; 2006Accessed August 2, 2011
16. Water sanitation and health. World Health Organization Web site. 2001 Available at: http://www.who.int/water-sanitation-health/ diseases/oncho/en. Accessed August 2, 2011
17. African Programme for Onchocerciasis Control (APOC): Ouagadougou (Burkina Faso): APOC; 2005. Final communiqué of the 11th session of the Joint Action Forum (JAF) of APOC, Paris, France, 6-9 December 2005
18. World Health Organization. Geneva: World Health Organization; 1995. Onchocerciasis and its control. Report of a WHO expert committee on onchocerciasis control. WHO Technical Report Series 1995;852:110
19. Allen JE, Adjei O, Bain O, et al. Of mice, cattle, and humans: the immunology and treatment of river blindness. PLoS Negl Trop Dis 2008;2:e217
20. US Bureau of the Census. U.S. Census Bureau Announces 2010 Census Population Counts e Apportionment Counts Delivered to President. Washington, DC, US Bureau of the Census. Available at: http:// 2010.census.gov/news/releases/ operations/cb10-cn93.html; 2010
21. Liesegang TJ, Melton LJ 3rd, Daly PJ, Ilstrup DM. Epidemiology of ocular herpes simplex. Incidence in Rochester, Minn, 1950 through 1982 Arch Ophthalmol 1989;107:1155-9 (Pubitemid 19195642)
22. Liesegang TJ. Biology and molecular aspects of herpes simplex and varicella-zoster virus infections. Ophthalmology 1992;99:781-99
23. Negrel AD, Thylefors B. The global impact of eye injuries. Ophthalmic Epidemiol 1998;5:143-67
24. Lim P, Fuchsluger TA, Jurkunas UV. Limbal stem cell deficiency and corneal neovascularization. Semin Ophthalmol 2009;24:139-48
25. Murube J. Aniridia and the ocular surface. Ocul Surf 2004;2:55-7 (Pubitemid 41263875)
26. Dana R. Comparison of topical interleukin-1 vs tumor necrosis factoralpha blockade with corticosteroid therapy on murine corneal inflammation, neovascularization, and transplant survival (an American Ophthalmological Society thesis). Trans Am Ophthalmol Soc 2007;105:330-43
27. Cornea donation & transplantation statistics. Eye Bank Association of America Web site. Available at: http://www.restoresight.org/about-us/ understanding-donation/cornea-donation-transplantation-statistics. Accessed September 6, 2011
28. Dana MR, Schaumberg DA, Kowal VO, et al. Corneal neovascularization after penetrating keratoplasty. Cornea 1995;14:604-9
29. Volker-Dieben HJ, D'Amaro J, Kok-Van Alphen CC. Hierarchy of prognostic factors for corneal allograft survival. Aust N Z J Ophthalmol 1987;15:11-8 (Pubitemid 17109890)
30. Rocha G, Deschênes J, Rowsey JJ. The immunology of corneal graft rejection. Crit Rev Immunol 1998;18:305-25 (Pubitemid 28364149)
31. The collaborative corneal transplantation studies (CCTS). Effectiveness of histocompatibility matching in high-risk corneal transplantation. The Collaborative Corneal Transplantation Studies Research Group. Arch Ophthalmol 1992;110:1392-403
32. Bachmann B, Taylor RS, Cursiefen C. Corneal neovascularization as a risk factor for graft failure and rejection after keratoplasty: an evidence-based meta-analysis. Ophthalmology 2010;117:1300-5.e7
33. Dana MR. Angiogenesis and lymphangiogenesis-implications for corneal immunity. Semin Ophthalmol 2006;21:19-22
34. Cursiefen C, Kuchle M, Naumann GO. Angiogenesis in corneal diseases: histopathologic evaluation of 254 human corneal buttons with neovascularization. Cornea 1998;17:611-3 (Pubitemid 28511907)
35. Barr J. 2004 Annual Report. Contact Lens Spectrum 2005, January
36. Suchecki JK, Donshik P, Ehlers WH. Contact lens complications. Ophthalmol Clin North Am 2003;16:471-84 (Pubitemid 37193808)
37. Cursiefen C, Kruse FE. Cornea and external eye disease. In: Reinhard T, Larkin DFP, eds. Essentials in ophthalmology. Germany, Springer, 2006. p. 83-99
38. Safvati A, Cole N, Hume E, Willcox M. Mediators of neovascularization and the hypoxic cornea. Curr Eye Res 2009;34:501-14
39. Weinberg RJ. Deep corneal vascularization caused by aphakic soft contact lens wear. Am J Ophthalmol 1977;83:121-2 (Pubitemid 8025668)
40. Donnenfeld ED, Ingraham H, Perry HD, et al. Contact lens-related deep stromal intracorneal hemorrhage. Ophthalmology 1991;98:1793-6
41. Carmeliet P. Angiogenesis in health and disease. Nat Med 2003;9:653-60 (Pubitemid 36749213)
42. Asahara T, Masuda H, Takahashi T, et al. Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ Res 1999;85:221-8 (Pubitemid 29377293)
43. Asahara T, Isner JM. Endothelial progenitor cells for vascular regeneration. J Hematother Stem Cell Res 2002;11:171-8 (Pubitemid 34309513)
44. Asahara T, Kawamoto A. Endothelial progenitor cells for postnatal vasculogenesis. Am J Physiol Cell Physiol 2004;287:C572-9 (Pubitemid 39095841)
45. Burger PC, Chandler DB, Klintworth GK. Experimental corneal neovascularization: biomicroscopic, angiographic, and morphologic correlation. Cornea 1985-1986;4:35-41
46. Ozerdem U, Alitalo K, Salven P, Li A. Contribution of bone marrowderived pericyte precursor cells to corneal vasculogenesis. Invest Ophthalmol Vis Sci 2005;46:3502-6 (Pubitemid 44264649)
47. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995;1:27-31
48. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996;86:353-64 (Pubitemid 26272076)
49. Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 1999;13:9-22 (Pubitemid 29038270)
50. Stuttfeld E, Ballmer-Hofer K. Structure and function of VEGF receptors. IUBMB Life 2009;61:915-22
51. Harper SJ, Bates DO. VEGF-A splicing: the key to antiangiogenic therapeutics? Nat Rev Cancer 2008;8:880-7
52. McCourt M, Wang JH, Sookhai S, Redmond HP. Proinflammatory mediators stimulate neutrophil-directed angiogenesis. Arch Surg 1999;134:1325-31discussion 1331-2
53. Shweiki D, Itin A, Soffer D, Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 1992;359(6398):843-5
54. Witmer AN, Vrensen GF, Van Noorden CJ, Schlingemann RO. Vascular endothelial growth factors and angiogenesis in eye disease. Prog Retin Eye Res 2003;22:1-29 (Pubitemid 36207453)
55. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003;9:669-76 (Pubitemid 36749215)
56. Bates DO, Hillman NJ, Williams B, et al. Regulation of microvascular permeability by vascular endothelial growth factors.JAnat 2002;200:581-97 (Pubitemid 34823050)
57. Hood JD, Meininger CJ, Ziche M, Granger HJ. VEGF upregulates ecNOS message, protein, and NO production in human endothelial cells. Am J Physiol 1998;274(3 Pt 2):H1054-8
58. Joukov V, Pajusola K, Kaipainen A, et al. A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. EMBO J 1996;15:290-8 (Pubitemid 26029207)
59. Achen MG, Jeltsch M, Kukk E, et al. Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4). Proc Natl Acad Sci U S A 1998;95: 548-53 (Pubitemid 28083780)
60. Luttun A, Tjwa M, Moons L, et al. Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1. Nat Med 2002;8:831-40
61. Cursiefen C, Chen L, Borges LP, et al. VEGF-A stimulates lymphangiogenesis and hemangiogenesis in inflammatory neovascularization via macrophage recruitment. J Clin Invest 2004;113:1040-50 (Pubitemid 38544126)
62. Amano S, Rohan R, Kuroki M, et al. Requirement for vascular endothelial growth factor in wound- and inflammation-related corneal neovascularization. Invest Ophthalmol Vis Sci 1998;39:18-22 (Pubitemid 28040457)
63. Philipp W, Speicher L, Humpel C. Expression of vascular endothelial growth factor and its receptors in inflamed and vascularized human corneas. Invest Ophthalmol Vis Sci 2000;41:2514-22 (Pubitemid 30624378)
64. Doctor PP, Bhat PV, Foster CS. Subconjunctival bevacizumab for corneal neovascularization. Cornea 2008;27:992-5
65. Oh JY, Kim MK, Wee WR. Subconjunctival and intracorneal bevacizumab injection for corneal neovascularization in lipid keratopathy. Cornea 2009;28:1070-3
66. Olsen SK, Garbi M, Zampieri N, et al. Fibroblast growth factor (FGF) homologous factors share structural but not functional homology with FGFs. J Biol Chem 2003;278:34226-36 (Pubitemid 37553265)
67. Itoh N, Ornitz DM. Evolution of the Fgf and Fgfr gene families. Trends Genet 2004;20:563-9 (Pubitemid 39314564)
68. Beenken A, Mohammadi M. The FGF family: biology, pathophysiology and therapy. Nat Rev Drug Discov 2009;8:235-53
69. Miller DL, Ortega S, Bashayan O, et al. Compensation by fibroblast growth factor 1 (FGF1) does not account for the mild phenotypic defects observed in FGF2 null mice. Mol Cell Biol 2000;20:2260-8 (Pubitemid 30123841)
70. Ware JA, Simons M. Angiogenesis in ischemic heart disease. Nat Med 1997;3:158-64 (Pubitemid 27064699)
71. Yanagisawa-Miwa A, Uchida Y, Nakamura F, et al. Salvage of infarcted myocardium by angiogenic action of basic fibroblast growth factor. Science 1992;257(5075):1401-3
72. Murakami M, Nguyen LT, Zhuang ZW, et al. The FGF system has a key role in regulating vascular integrity. J Clin Invest 2008;118:3355-66
73. Adamis AP, Meklir B, Joyce NC. In situ injury-induced release of basic-fibroblast growth factor from corneal epithelial cells. Am J Pathol 1991;139:961-7
74. Folkman J, Klagsbrun M, Sasse J, et al. A heparin-binding angiogenic proteinebasic fibroblast growth factoreis stored within basement membrane. Am J Pathol 1988;130:393-400 (Pubitemid 18076374)
75. Soubrane G, Jerdan J, Karpouzas I, et al. Binding of basic fibroblast growth factor to normal and neovascularized rabbit cornea. Invest Ophthalmol Vis Sci 1990;31:323-33 (Pubitemid 20072698)
76. Dastjerdi MH, Sadrai Z, Saban DR, et al. Corneal penetration of topical and subconjunctival bevacizumab (Avastin). Invest Ophthalmol Vis Sci 2011;52:8718-23
77. Hoch RV, Soriano P. Roles of PDGF in animal development. Development 2003;130:4769-84 (Pubitemid 37321862)
78. McDonald JA, Pinheiro EM, Montell DJ. PVF1, a PDGF/VEGF homolog, is sufficient to guide border cells and interacts genetically with Taiman. Development 2003;130:3469-78 (Pubitemid 37010010)
79. Munier AI, Doucet D, Perrodou E, et al. PVF2, a PDGF/VEGF-like growth factor, induces hemocyte proliferation in Drosophila larvae. EMBO Rep 2002;3:1195-200 (Pubitemid 36105010)
80. Fredriksson L, Li H, Eriksson U. The PDGF family: four gene products form five dimeric isoforms. Cytokine Growth Factor Rev 2004;15:197-204 (Pubitemid 38781045)
81. Levéen P, Pekny M, Gebre-Medhin S, et al. Mice deficient for PDGF B show renal, cardiovascular, and hematological abnormalities. Genes Dev 1994;8:1875-87 (Pubitemid 24273888)
82. Soriano P. Abnormal kidney development and hematological disorders in PDGF beta-receptor mutant mice. Genes Dev 1994;8:1888-96
83. Lindahl P, Johansson BR, Levéen P, Betsholtz C. Pericyte loss and microaneurysm formation in PDGF-B-deficient mice. Science 1997;277(5323):242-5 (Pubitemid 27446080)
84. Hellström M, Kalén M, Lindahl P, et al. Role of PDGF-B and PDGFRbeta in recruitment of vascular smooth muscle cells and pericytes during embryonic blood vessel formation in the mouse. Development 1999;126:3047-55 (Pubitemid 29378170)
85. Kim WJ, Mohan RR, Mohan RR, Wilson SE. Effect of PDGF, IL- 1alpha, and BMP2/4 on corneal fibroblast chemotaxis: expression of the platelet-derived growth factor system in the cornea. Invest Ophthalmol Vis Sci 1999;40:1364-72 (Pubitemid 29252327)
86. Vesaluoma M, Teppo AM, Grönhagen-Riska C, Tervo T. Plateletderived growth factor-BB (PDGF-BB) in tear fluid: a potential modulator of corneal wound healing following photorefractive keratectomy. Curr Eye Res 1997;16:825-31 (Pubitemid 27354982)
87. Hoppenreijs VP, Pels E, Vrensen GF, et al. Platelet-derived growth factor: receptor expression in corneas and effects on corneal cells. Invest Ophthalmol Vis Sci 1993;34:637-49 (Pubitemid 23095218)
88. Dell S, Peters S, Müther P, et al. The role of PDGF receptor inhibitors and PI3-kinase signaling in the pathogenesis of corneal neovascularization. Invest Ophthalmol Vis Sci 2006;47:1928-37 (Pubitemid 46768273)
89. Augustin HG, Koh GY, Thurston G, Alitalo K. Control of vascular morphogenesis and homeostasis through the angiopoietin-Tie system. Nat Rev Mol Cell Biol 2009;10:165-77
90. Valenzuela DM, Griffiths JA, Rojas J, et al. Angiopoietins 3 and 4: diverging gene counterparts in mice and humans. Proc Natl Acad Sci U S A 1999;96:1904-9 (Pubitemid 29117840)
91. Maisonpierre PC, Suri C, Jones PF, et al. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 1997;277(5322):55-60 (Pubitemid 27450643)
92. Suri C, Jones PF, Patan S, et al. Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell 1996;87:1171-80 (Pubitemid 27010101)
93. Loughna S, Sato TN. Angiopoietin and Tie signaling pathways in vascular development. Matrix Biol 2001;20(5-6):319-25 (Pubitemid 32846717)
94. Asahara T, Chen D, Takahashi T, et al. Tie2 receptor ligands, angiopoietin-1 and angiopoietin-2, modulate VEGF-induced postnatal neovascularization. Circ Res 1998;83:233-40 (Pubitemid 28371312)
95. Lobov IB, Brooks PC, Lang RA. Angiopoietin-2 displays VEGFdependent modulation of capillary structure and endothelial cell survival in vivo. Proc Natl Acad Sci U S A 2002;99:11205-10 (Pubitemid 34920903)
96. Ghajar CM, George SC, Putnam AJ. Matrix metalloproteinase control of capillary morphogenesis. Crit Rev Eukaryot Gene Expr 2008;18:251-78 (Pubitemid 351620287)
97. Mignatti P, Tsuboi R, Robbins E, Rifkin DB. In vitro angiogenesis on the human amniotic membrane: requirement for basic fibroblast growth factor-induced proteinases. J Cell Biol 1989;108:671-82 (Pubitemid 19065862)
98. Cornelius LA, Nehring LC, Roby JD, et al. Human dermal microvascular endothelial cells produce matrix metalloproteinases in response to angiogenic factors and migration. J Invest Dermatol 1995;105:170-6
99. Hanemaaijer R, Koolwijk P, Le Clercq L, et al. Regulation of matrix metalloproteinase expression in human vein and microvascular endothelial cells. Biochem J 1993;296:803-9
100. Unemori EN, Bouhana KS, Werb Z. Vectorial secretion of extracellular matrix proteins, matrix-degrading proteinases, and tissue inhibitor of metalloproteinases by endothelial cells. J Biol Chem 1990;265:445-51
101. Itoh T, Tanioka M, Yoshida H, et al. Reduced angiogenesis and tumor progression in gelatinase A-deficient mice. Cancer Res 1998;58:1048-51 (Pubitemid 28182477)
102. Fang J, Shing Y, Wiederschain D, et al. Matrix metalloproteinase-2 is required for the switch to the angiogenic phenotype in a tumor model. Proc Natl Acad Sci U S A 2000;97:3884-9 (Pubitemid 30226056)
103. Bergers G, Brekken R, McMahon G, et al. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol 2000;2:737-44
104. Lee S, Jilani SM, Nikolova GV, et al. Processing of VEGF-A by matrix metalloproteinases regulates bioavailability and vascular patterning in tumors. J Cell Biol 2005;169:681-91 (Pubitemid 41002860)
105. Masson V, de la Ballina LR, Munaut C, et al. Contribution of host MMP-2 and MMP-9 to promote tumor vascularization and invasion of malignant keratinocytes. FASEB J 2005;19:234-6 (Pubitemid 40189266)
106. Jeong JW, Cha HJ, Yu DY, et al. Induction of membrane-type matrix metalloproteinase-1 stimulates angiogenic activities of bovine aortic endothelial cells. Angiogenesis 1999;3:167-74
107. Zhou Z, Apte SS, Soininen R, et al. Impaired endochondral ossification and angiogenesis in mice deficient in membrane-type matrix metalloproteinase I. Proc Natl Acad Sci U S A 2000;97:4052-7 (Pubitemid 30226085)
108. Chun TH, Sabeh F, Ota I, et al. MT1-MMP-dependent neovessel formation within the confines of the three-dimensional extracellular matrix. J Cell Biol 2004;167:757-67 (Pubitemid 39565155)
109. Ye HQ, Azar DT. Expression of gelatinases A and B, and TIMPs 1 and 2 during corneal wound healing. Invest Ophthalmol Vis Sci 1998;39:913-21 (Pubitemid 28196677)
110. Kato T, Kure T, Chang JH, et al. Diminished corneal angiogenesis in gelatinase A-deficient mice. FEBS Lett 2001;508:187-90 (Pubitemid 33079244)
111. Samolov B, Steen B, Seregard S, et al. Delayed inflammation-associated corneal neovascularization in MMP-2-deficient mice. Exp Eye Res 2005;80:159-66
112. Mimura T, Han KY, Onguchi T, et al. MT1-MMP-mediated cleavage of decorin in corneal angiogenesis. J Vasc Res 2009;46:541-50
113. Azar DT, Casanova FH, Mimura T, et al. Effect of MT1-MMP deficiency and overexpression in corneal keratocytes on vascular endothelial cell migration and proliferation. Curr Eye Res 2008;33:954-62
114. Azar DT, Casanova FH, Mimura T, et al. Corneal epithelial MT1- MMP inhibits vascular endothelial cell proliferation and migration. Cornea 2010;29:321-30
115. Li J, Perrella MA, Tsai JC, et al. Induction of vascular endothelial growth factor gene expression by interleukin-1 beta in rat aortic smooth muscle cells. J Biol Chem 1995;270:308-12
116. Cohen T, Nahari D, Cerem LW, et al. Interleukin 6 induces the expression of vascular endothelial growth factor. J Biol Chem 1996;271:736-41 (Pubitemid 26034921)
117. Ryuto M, Ono M, Izumi H, et al. Induction of vascular endothelial growth factor by tumor necrosis factor alpha in human glioma cells. Possible roles of SP-1. J Biol Chem 1996;271:28220-8 (Pubitemid 26374633)
118. Pertovaara L, Kaipainen A, Mustonen T, et al. Vascular endothelial growth factor is induced in response to transforming growth factorbeta in fibroblastic and epithelial cells. J Biol Chem 1994;269:6271-4 (Pubitemid 24190991)
119. Li A, Dubey S, Varney ML, et al. IL-8 directly enhanced endothelial cell survival, proliferation, and matrix metalloproteinases production and regulated angiogenesis. J Immunol 2003;170:3369-76 (Pubitemid 36302216)
120. Sun J. Matrix metalloproteinases and tissue inhibitor of metalloproteinases are essential for the inflammatory response in cancer cells. J Signal Transduct 2010;2010:985132
121. Chen L, Huq S, Gardner H, et al. Very late antigen 1 blockade markedly promotes survival of corneal allografts. Arch Ophthalmol 2007;125:783-8 (Pubitemid 46919739)
122. Senger DR, Perruzzi CA, Streit M, et al. The alpha(1)beta(1) and alpha(2)beta(1) integrins provide critical support for vascular endothelial growth factor signaling, endothelial cell migration, and tumor angiogenesis. Am J Pathol 2002;160:195-204 (Pubitemid 34052280)
123. Nakao S, Hata Y, Miura M, et al. Dexamethasone inhibits interleukin- 1beta induced corneal neovascularization: role of nuclear factorkappaB- activated stromal cells in inflammatory angiogenesis. Am J Pathol 2007;171:1058-65 (Pubitemid 47441002)
124. Ebrahem Q, Minamoto A, Hoppe G, et al. Triamcinolone acetonide inhibits IL-6- and VEGF-induced angiogenesis downstream of the IL-6 and VEGF receptors. Invest Ophthalmol Vis Sci 2006;47:4935-41 (Pubitemid 46586396)
125. Ambati BK, Nozaki M, Singh N, et al. Corneal avascularity is due to soluble VEGF receptor-1. Nature 2006;443(7114):993-7 (Pubitemid 44646176)
126. Ambati BK, Patterson E, Jani P, et al. Soluble vascular endothelial growth factor receptor-1 contributes to the corneal antiangiogenic barrier. Br J Ophthalmol 2007;91:505-8 (Pubitemid 46623686)
127. Kendall RL, Thomas KA. Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. Proc Natl Acad Sci U S A 1993;90:10705-9 (Pubitemid 23347111)
128. Kendall RL,Wang G,ThomasKA. Identification of a natural soluble form of the vascular endothelial growth factor receptor, FLT-1, and its heterodimerization with KDR. Biochem Biophys Res Commun 1996;226:324-8 (Pubitemid 26331903)
129. Albuquerque RJ, Hayashi T, Cho WG, et al. Alternatively spliced vascular endothelial growth factor receptor-2 is an essential endogenous inhibitor of lymphatic vessel growth. Nat Med 2009;15:1023-30
130. Cursiefen C, Chen L, Saint-Geniez M, et al. Nonvascular VEGF receptor 3 expression by corneal epithelium maintains avascularity and vision. Proc Natl Acad Sci U S A 2006;103:11405-10 (Pubitemid 44156530)
131. Chung ES, Chauhan SK, Jin Y, et al. Contribution of macrophages to angiogenesis induced by vascular endothelial growth factor receptor- 3-specific ligands. Am J Pathol 2009;175:1984-92
132. Simonovic M, Gettins PG, Volz K. Crystal structure of human PEDF, a potent antiangiogenic and neurite growth-promoting factor. Proc Natl Acad Sci U S A 2001;98:11131-5 (Pubitemid 32928694)
133. Filleur S, Nelius T, de Riese W, Kennedy RC. Characterization of PEDF: a multi-functional serpin family protein. J Cell Biochem 2009;106:769-75
134. Dawson DW, Volpert OV, Gillis P, et al. Pigment epithelium-derived factor: a potent inhibitor of angiogenesis. Science 1999;285(5425):245-8 (Pubitemid 29329995)
135. Zamiri P, Masli S, Streilein JW, Taylor AW. Pigment epithelial growth factor suppresses inflammation by modulating macrophage activation. Invest Ophthalmol Vis Sci 2006;47:3912-8 (Pubitemid 46044306)
136. Becerra SP. Structure-function studies on PEDF. A noninhibitory serpin with neurotrophic activity. Adv Exp Med Biol 1997;425:223-37 (Pubitemid 28035786)
137. Duh EJ, Yang HS, Suzuma I, et al. Pigment epithelium-derived factor suppresses ischemia-induced retinal neovascularization and VEGFinduced migration and growth. Invest Ophthalmol Vis Sci 2002;43:821-9 (Pubitemid 34184503)
138. Mori K, Gehlbach P, Ando A, et al. Regression of ocular neovascularization in response to increased expression of pigment epitheliumderived factor. Invest Ophthalmol Vis Sci 2002;43:2428-34 (Pubitemid 34700678)
139. Karakousis PC, John SK, Behling KC, et al. Localization of pigment epithelium derived factor (PEDF) in developing and adult human ocular tissues. Mol Vis 2001;7:154-63 (Pubitemid 36153665)
140. Ogata N, Wada M, Otsuji T, et al. Expression of pigment epitheliumderived factor in normal adult rat eye and experimental choroidal neovascularization. Invest Ophthalmol Vis Sci 2002;43:1168-75 (Pubitemid 34258289)
141. Meyer C, Notari L, Becerra SP. Mapping the type I collagen-binding site on pigment epithelium-derived factor. Implications for its antiangiogenic activity. J Biol Chem 2002;277:45400-7 (Pubitemid 36159148)
142. Jin J, Ma JX, Guan M, Yao K. Inhibition of chemical cautery-induced corneal neovascularization by topical pigment epithelium-derived factor eyedrops. Cornea 2010;29:1055-61
143. O'Reilly MS, Holmgren L, Shing Y, et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994;79:315-28 (Pubitemid 24324921)
144. Patterson BC, Sang QA. Angiostatin-converting enzyme activities of human matrilysin (MMP-7) and gelatinase B/type IV collagenase (MMP-9). J Biol Chem 1997;272:28823-5 (Pubitemid 27498157)
145. Moser TL, Stack MS, Asplin I, et al. Angiostatin binds ATP synthase on the surface of human endothelial cells. Proc Natl Acad Sci U S A 1999;96:2811-6 (Pubitemid 29148800)
146. Moser TL, Kenan DJ, Ashley TA, et al. Endothelial cell surface F1-F0 ATP synthase is active in ATP synthesis and is inhibited by angiostatin. Proc Natl Acad Sci U S A 2001;98:6656-61 (Pubitemid 32538272)
147. Troyanovsky B, Levchenko T, Månsson G, et al. Angiomotin: an angiostatin binding protein that regulates endothelial cell migration and tube formation. J Cell Biol 2001;152:1247-54 (Pubitemid 34280181)
148. Tarui T, Miles LA, Takada Y. Specific interaction of angiostatin with integrin alpha(v)beta(3) in endothelial cells. J Biol Chem 2001;276: 39562-8
149. Wajih N, Sane DC. Angiostatin selectively inhibits signaling by hepatocyte growth factor in endothelial and smooth muscle cells. Blood 2003;101:1857-63 (Pubitemid 36237585)
150. Coffer PJ, Jin J, Woodgett JR. Protein kinase B (c-Akt): a multifunctional mediator of phosphatidylinositol 3-kinase activation. Biochem J 1998;335:1-13 (Pubitemid 28477043)
151. Mirza AM, Kohn AD, Roth RA, McMahon M. Oncogenic transformation of cells by a conditionally active form of the protein kinase Akt/ PKB. Cell Growth Differ 2000;11:279-92 (Pubitemid 30457777)
152. Albini A, Brigati C, Ventura A, et al. Angiostatin antiangiogenesis requires IL-12: the innate immune system as a key target. J Transl Med 2009;7:5
153. Benelli R, Morini M, Carrozzino F, et al. Neutrophils as a key cellular target for angiostatin: implications for regulation of angiogenesis and inflammation. FASEB J 2002;16:267-9
154. Chavakis T, Athanasopoulos A, Rhee JS, et al. Angiostatin is a novel anti-inflammatory factor by inhibiting leukocyte recruitment. Blood 2005;105:1036-43 (Pubitemid 40170873)
155. Sack RA, Beaton AR, Sathe S. Diurnal variations in angiostatin in human tear fluid: a possible role in prevention of corneal neovascularization. Curr Eye Res 1999;18:186-93 (Pubitemid 29213833)
156. Gabison E, Chang JH, Hernández-Quintela E, et al. Antiangiogenic role of angiostatin during corneal wound healing. Exp Eye Res 2004;78:579-89 (Pubitemid 38183337)
157. Ambati BK, Joussen AM, Ambati J, et al. Angiostatin inhibits and regresses corneal neovascularization. Arch Ophthalmol 2002;120:1063-8 (Pubitemid 34856074)
158. O'Reilly MS, Boehm T, Shing Y, et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997;88:277-85 (Pubitemid 28015876)
159. Muragaki Y, Timmons S, Griffith CM, et al. Mouse Col18a1 is expressed in a tissue-specific manner as three alternative variants and is localized in basement membrane zones. Proc Natl Acad Sci U S A 1995;92(19):8763-7
160. Rehn M, Pihlajaniemi T. Alpha 1(XVIII), a collagen chain with frequent interruptions in the collagenous sequence, a distinct tissue distribution, and homology with type XV collagen. Proc Natl Acad Sci U S A 1994;91:4234-8
161. Rehn M, Hintikka E, Pihlajaniemi T. Primary structure of the alpha 1 chain of mouse type XVIII collagen, partial structure of the corresponding gene, and comparison of the alpha 1(XVIII) chain with its homologue, the alpha 1(XV) collagen chain. J Biol Chem 1994;269(19):13929-35
162. Saarela J, Rehn M, Oikarinen A, et al. The short and long forms of type XVIII collagen show clear tissue specificities in their expression and location in basement membrane zones in humans. Am J Pathol 1998;153:611-26 (Pubitemid 28373671)
163. Ferreras M, Felbor U, Lenhard T, et al. Generation and degradation of human endostatin proteins by various proteinases. FEBS Lett 2000;486:247-51
164. Kim YM, Hwang S, Kim YM, et al. Endostatin blocks vascular endothelial
165. Sertié AL, Sossi V, Camargo AA, et al. Collagen XVIII, containing an endogenous inhibitor of angiogenesis and tumor growth, plays a critical role in the maintenance of retinal structure and in neural tube closure (Knobloch syndrome). Hum Mol Genet 2000;9:2051-8 (Pubitemid 30642670)
166. Fukai N, Eklund L, Marneros AG, et al. Lack of collagen XVIII/endostatin results in eye abnormalities. EMBO J 2002;21:1535-44 (Pubitemid 34614610)
167. Lin HC, Chang JH, Jain S, et al. Matrilysin cleavage of corneal collagen type XVIII NC1 domain and generation of a 28-kDa fragment. Invest Ophthalmol Vis Sci 2001;42:2517-24 (Pubitemid 32954857)
168. Yu Y, Moulton KS, Khan MK, et al. E-selectin is required for the antiangiogenic activity of endostatin. ProcNatl Acad SciUS A 2004;101:8005-10 (Pubitemid 38698044)
169. Chang JH, Javier JA, Chang GY, et al. Functional characterization of neostatins, the MMP-derived, enzymatic cleavage products of type XVIII collagen. FEBS Lett 2005;579(17):3601-6 (Pubitemid 40897698)
170. Kojima T, Azar DT, Chang JH. Neostatin-7 regulates bFGF-induced corneal lymphangiogenesis. FEBS Lett 2008;582(17):2515-20
171. Mundel TM, Kalluri R. Type IV collagen-derived angiogenesis inhibitors. Microvasc Res 2007;74(2-3):85-9 (Pubitemid 350051026)
172. WangY,YinH,ChenP,XieL,WangY. Inhibitory effect of canstatininalkali burn-induced corneal neovascularization. Ophthalmic Res 2011;46:66-72
173. Huo N, Ichikawa Y, Kamiyama M, et al. MMP-7 (matrilysin) accelerated growth of human umbilical vein endothelial cells. Cancer Lett 2002;177:95-100 (Pubitemid 34102404)
174. Ito TK, Ishii G, Chiba H, Ochiai A. The VEGF angiogenic switch of fibroblasts is regulated by MMP-7 from cancer cells. Oncogene 2007;26:7194-203 (Pubitemid 350085324)
175. Ito TK, Ishii G, Saito S, et al. Degradation of soluble VEGF receptor-1 by MMP-7 allows VEGF access to endothelial cells. Blood 2009;113:2363-9
176. Lu PC, Ye H, Maeda M, Azar DT. Immunolocalization and gene expression of matrilysin during corneal wound healing. Invest Ophthalmol Vis Sci 1999;40:20-7 (Pubitemid 29029567)
177. Kure T, Chang JH, Kato T, et al. Corneal neovascularization after excimer keratectomy wounds in matrilysin-deficient mice. Invest Ophthalmol Vis Sci 2003;44:137-44 (Pubitemid 36134266)
178. Yeh SI, Han KY, Sabri A, et al. MMP-7 knock-in corneal fibroblast cell lines secrete MMP-7 with proteolytic activity towards collagen XVIII. Curr Eye Res 2010;35:799-805
179. Panetti TS, Chen H, Misenheimer TM, et al. Endothelial cell mitogenesis induced by LPA: inhibition by thrombospondin-1 and thrombospondin-2. J Lab Clin Med 1997;129:208-16 (Pubitemid 27134066)
180. Taraboletti G, Roberts D, Liotta LA, Giavazzi R. Platelet thrombospondin modulates endothelial cell adhesion, motility, and growth: a potential angiogenesis regulatory factor. J Cell Biol 1990;111:765-72
181. Iruela-Arispe ML, Bornstein P, Sage H. Thrombospondin exerts an antiangiogenic effect on cord formation by endothelial cells in vitro. Proc Natl Acad Sci U S A 1991;88:5026-30 (Pubitemid 21914676)
182. Jiménez B, Volpert OV, Crawford SE, et al. Signals leading to apoptosis-dependent inhibition of neovascularization by thrombospondin-1 Nat Med 2000;6:41-8 (Pubitemid 30048524)
183. Hiscott P, Seitz B, Schlötzer-Schrehardt U, Naumann GO. Immunolocalisation of thrombospondin 1 in human, bovine and rabbit cornea. Cell Tissue Res 1997;289:307-10 (Pubitemid 27326654)
184. Cursiefen C, Masli S, Ng TF, et al. Roles of thrombospondin-1 and -2 in regulating corneal and iris angiogenesis. Invest Ophthalmol Vis Sci 2004;45:1117-24 (Pubitemid 38869016)
185. Mwaikambo BR, Sennlaub F, Ong H, et al. Activation of CD36 inhibits and induces regression of inflammatory corneal neovascularization. Invest Ophthalmol Vis Sci 2006;47:4356-64 (Pubitemid 46579359)
186. Cursiefen C, Maruyama K, Bock F, et al. Thrombospondin 1 inhibits inflammatory lymphangiogenesis by CD36 ligation on monocytes. J Exp Med 2011;208:1083-92
187. Mwaikambo BR, Sennlaub F, Ong H, et al. Genetic ablation of CD36 induces age-related corneal neovascularization. Cornea 2008;27:1037-41
188. Griffith TS, Brunner T, Fletcher SM, et al. Fas ligand-induced apoptosis as a mechanism of immune privilege. Science 1995;270(5239):1189-92
189. Griffith TS, Yu X, Herndon JM, et al. CD95-induced apoptosis of lymphocytes in an immune privileged site induces immunological tolerance. Immunity 1996;5:7-16 (Pubitemid 26254781)
190. Stuart PM, Pan F, Plambeck S, Ferguson TA. FasL-Fas interactions regulate neovascularization in the cornea. Invest Ophthalmol Vis Sci 2003;44:93-8 (Pubitemid 36134260)
191. Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 2008;26:677-704 (Pubitemid 351600389)
192. Jin Y, Chauhan SK, Annan JE, et al. A novel function for programmed death ligand-1 regulation of angiogenesis. Am J Pathol 2011;178:1922-9
193. Chang JH, Gabison EE, Kato T, et al. Corneal neovascularization. Curr Opin Ophthalmol 2001;12:242-9 (Pubitemid 32751680)
194. Cursiefen C,Wenkel H,Martus P, et al.Impact of short-term versus longterm topical steroids on corneal neovascularization after non-high-risk keratoplasty. Graefes Arch Clin Exp Ophthalmol 2001;239:514-21 (Pubitemid 32725422)
195. Wahl SM. Corticosteroid inhibition of chemotactic lymphokine production by T and B lymphocytes. Ann N Y Acad Sci 1975;256:375-85
196. Claman HN. Corticosteroids and lymphoid cells. N Engl J Med 1972;287:388-97
197. Snyder DS, Unanue ER. Corticosteroids inhibit murine macrophage Ia expression and interleukin 1 production. J Immunol 1982;129:1803-5 (Pubitemid 12004324)
198. Waage A, Slupphaug G, Shalaby R. Glucocorticoids inhibit the production of IL6 from monocytes, endothelial cells and fibroblasts. Eur J Immunol 1990;20:2439-43
199. Jørgensen KA, Stoffersen E. Hydrocortisone inhibits platelet prostaglandin and endothelial prostacyclin production. Pharmacol Res Commun 1981;13:579-86 (Pubitemid 11089566)
200. Takahashi K, Saishin Y, Saishin Y, et al. Topical nepafenac inhibits ocular neovascularization. Invest Ophthalmol Vis Sci 2003;44:409-15 (Pubitemid 36134303)
201. Frucht J, Zauberman H. Topical indomethacin effect on neovascularization of the cornea and on prostaglandin E2 levels. Br J Ophthalmol 1984;68:656-9 (Pubitemid 15136079)
202. BenEzra D. Neovasculogenic ability of prostaglandins, growth factors, and synthetic chemoattractants. Am J Ophthalmol 1978;86:455-61 (Pubitemid 9000001)
203. Guidera AC, Luchs JI, Udell IJ. Keratitis, ulceration, and perforation associated with topical nonsteroidal anti-inflammatory drugs. Ophthalmology 2001;108:936-44 (Pubitemid 32374251)
204. Halldorsson T. Alteration of optical and thermal properties of blood by Nd:YAG laser irradiation. Proceedings of the 4th congress of the international society for laser surgery. Tokyo, Japan, Nov 23-27, 1981
205. Nirankari VS. Laser photocoagulation for corneal stromal vascularization. Trans Am Ophthalmol Soc 1992;90:595-669
206. Baer JC, Foster CS. Corneal laser photocoagulation for treatment of neovascularization. Efficacy of 577 nm yellow dye laser. Ophthalmology 1992;99:173-9
207. Parsa CF, Temprano J, Wilson D, et al.Hemorrhage complicatingYAGlaser feeder vessel coagulation of cornea vascularization. Cornea 1994;13:264-8 (Pubitemid 24129163)
208. Cherry PM, Garner A. Corneal neovascularization treated with argon laser. Br J Ophthalmol 1976;60:464-72
209. Marsh RJ, Marshall J. Treatment of lipid keratopathy with argon laser. Br J Ophthalmol 1982;66:127-35 (Pubitemid 12166864)
210. Marsh RJ. Argon laser treatment of lipid keratopathy. Br J Ophthalmol 1988;72:900-4 (Pubitemid 19022864)
211. Nirankari VS, Baer JC. Corneal argon laser photocoagulation for neovascularization in penetrating keratoplasty. Ophthalmology 1986;93:1304-9 (Pubitemid 16008994)
212. Gerten G. Bevacizumab (avastin) and argon laser to treat neovascularization in corneal transplant surgery. Cornea 2008;27:1195-9
213. Pai VH, Handary SV. Necrotizing scleritis following laser therapy for corneal vascularization. Ann Ophthalmol 2009;41:50-1
214. Macdonald IJ, Dougherty TJ. Basic principles of photodynamic therapy. J Porphyrins Phthalocyanines 2001;5:105-29 (Pubitemid 32125231)
215. Weishaupt KR, Gomer CJ, Dougherty TJ. Identification of singlet oxygen as the cytotoxic agent in photo-inactivation of a murine tumor. Cancer Res 1976;36:2326-9
216. Reed MW, Miller FN, Wieman TJ, et al. The effect of photodynamic therapy on the microcirculation. J Surg Res 1988;45:452-9 (Pubitemid 18260086)
217. Fingar VH. Vascular effects of photodynamic therapy. J Clin Laser Med Surg 1996;14:323-8 (Pubitemid 26405724)
218. Fossarello M, Peiretti E, Zucca I, et al. Photodynamic therapy of corneal neovascularization with verteporfin. Cornea 2003;22: 485-8 (Pubitemid 36759046)
219. Yoon KC, You IC, Kang IS, et al. Photodynamic therapy with verteporfin for corneal neovascularization. Am J Ophthalmol 2007;144:390-5
220. Gordon YJ, Mann RK, Mah TS, et al. Fluorescein-potentiated argon laser therapy improves symptoms and appearance of corneal neovascularization. Cornea 2002;21:770-3 (Pubitemid 35239497)
221. Sheppard JD Jr, Epstein RJ, Lattanzio FA Jr, et al. Argon laser photodynamic therapy of human corneal neovascularization after intravenous administration of dihematoporphyrin ether. Am J Ophthalmol 2006;141:524-9
222. Corrent G, Roussel TJ, Tseng SCG, et al. Promotion of graft survival by photothrombotic occlusion of corneal neovascularization. Arch Ophthalmol 1989;107:1051-6
223. Brooks BJ, Ambati BK, Marcus DM, Ratanasit A. Photodynamic therapy for corneal neovascularisation and lipid degeneration. Br J Ophthalmol 2004;88:840 (Pubitemid 38725605)
224. You IC, Im SK, Lee SH, Yoon KC. Photodynamic therapy with verteporfin combined with subconjunctival injection of bevacizumab for corneal neovascularization. Cornea 2011;30:30-3
225. Pillai CT, Dua HS, Hossain P. Fine needle diathermy occlusion of corneal vessels. Invest Ophthalmol Vis Sci 2000;41:2148-53 (Pubitemid 30450986)
226. Wertheim MS, Cook SD, Knox-Cartwright NE, et al. Electrolysis-needle cauterization of corneal vessels in patients with lipid keratopathy. Cornea 2007;26:230-1 (Pubitemid 46168300)
227. Thatte S. Fine needle diathermy - A choice for managing corneal vascularization. Nepal J Ophthalmol 2011;3:23-6
228. Kenyon KR, Tseng SC. Limbal autograft transplantation for ocular surface disorders. Ophthalmology 1989;96:709-22discussion 722-3
229. Solomon A, Ellies P, Anderson DF, et al. Long-term outcome of keratolimbal allograft with or without penetrating keratoplasty for total limbal stem cell deficiency. Ophthalmology 2002;109:1159-66 (Pubitemid 34546927)
230. Pellegrini G, Traverso CE, Franzi AT, et al. Long-term restoration of damaged corneal surfaces with autologous cultivated corneal epithelium. Lancet 1997;349(9057):990-3 (Pubitemid 27149803)
231. Pauklin M, Steuhl KP, Meller D. Characterization of the corneal surface in limbal stem cell deficiency and after transplantation of cultivated limbal epithelium. Ophthalmology 2009;116:1048-56
232. Ono K, Yokoo S, Mimura T, et al. Autologous transplantation of conjunctival epithelial cells cultured on amniotic membrane in a rabbit model. Mol Vis 2007;13:1138-43 (Pubitemid 47082968)
233. Ang LP, Tanioka H, Kawasaki S, et al. Cultivated human conjunctival epithelial transplantation for total limbal stem cell deficiency. Invest Ophthalmol Vis Sci 2010;51:758-64
234. Sippel KC, Ma JJ, Foster CS. Amniotic membrane surgery. Curr Opin Ophthalmol 2001;12:269-81 (Pubitemid 32751684)
235. Tseng SC, Espana EM, Kawakita T, et al. How does amniotic membrane work? Ocul Surf 2004;2:177-87 (Pubitemid 41263868)
236. Cauchi PA, Ang GS, Azuara-Blanco A, Burr JM. A systematic literature review of surgical interventions for limbal stem cell deficiency in humans. Am J Ophthalmol 2008;146:251-9
237. Kheirkhah A, Casas V, Raju VK, Tseng SC. Sutureless amniotic membrane transplantation for partial limbal stem cell deficiency. Am J Ophthalmol 2008;145:787-94
238. Ferrara N, Hillan KJ, Gerber HP, Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 2004;3:391-400 (Pubitemid 38618122)
239. Iturralde D, Spaide RF, Meyerle CB, et al. Intravitreal bevacizumab (Avastin) treatment of macular edema in central retinal vein occlusion: a short-term study. Retina 2006;26:279-84 (Pubitemid 44318180)
240. Iliev ME, Domig D, Wolf-Schnurrbursch U, et al. Intravitreal bevacizumab (Avastin) in the treatment of neovascular glaucoma. Am J Ophthalmol 2006;142:1054-6 (Pubitemid 44853889)
241. Avastin package insert. South San Francisco, CA, Genentech, Inc, 2009
242. Thiel MA, Coster DJ, Standfield SD, et al. Penetration of engineered antibody fragments into the eye. Clin Exp Immunol 2002;128:67-74 (Pubitemid 34451181)
243. Brereton HM, Taylor SD, Farrall A, et al. Influence of format on in vitro penetration of antibody fragments through porcine cornea. Clin Exp Immunol 2002;128:67-74
244. DeStafeno JJ, Kim T. Topical bevacizumab therapy for corneal neovascularization. Arch Ophthalmol 2007;125:834-6 (Pubitemid 46919748)
245. Bock F, König Y, Kruse F, et al. Bevacizumab (Avastin) eye drops inhibit corneal neovascularization. Graefes Arch Clin Exp Ophthalmol 2008;246:281-4 (Pubitemid 351149633)
246. Kim SW, Ha BJ, Kim EK, et al. The effect of topical bevacizumab on corneal neovascularization. Ophthalmology 2008;115:e33-8
247. Dastjerdi MH, Al-Arfaj KM, Nallasamy N, et al. Topical bevacizumab in the treatment of corneal neovascularization: results of a prospective, open-label, noncomparative study. Arch Ophthalmol 2009;127:381-9
248. Koenig Y, Bock F, Horn F, et al. Short- and long-term safety profile and efficacy of topical bevacizumab (Avastin) eye drops against corneal neovascularization. Graefes Arch Clin Exp Ophthalmol 2009;247:1375-82
249. Gaudreault J, Fei D, Rusit J, et al. Preclinical pharmacokinetics of Ranibizumab (rhuFabV2) after a single intravitreal administration. Invest Ophthalmol Vis Sci 2005;46:726-33 (Pubitemid 40270359)
250. Ferrari G, Okanobo A, Dastjerdi M, et al. Topical ranibizumab as a treatment of corneal neovascularization. Manuscript submitted for publication, 2011.
251. Cheng SF, Ferrari G, Okanobo A, et al. Sustained efficacy of topical bevacizumab in the treatment of corneal neovascularization (NV). Invest Ophthalmol Vis Sci 2011. ARVO:6399-D863
252. Group CR, Martin DF, Maguire MG, et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 2011;364:1897-908
253. Steinbrook R. The price of sighteranibizumab, bevacizumab, and the treatment of macular degeneration. N Engl J Med 2006;355:1409-12 (Pubitemid 44511554)
254. Rosenstein JM, Krum JM. New roles for VEGF in nervous tissueebeyond blood vessels. Exp Neurol 2004;187:246-53 (Pubitemid 38610271)
255. Van der Reis MI, La Heij EC, Jong-Hesse YD, et al. A systematic review of the adverse events of intravitreal anti-vascular endothelial growth factor injections. Retina 2011;31:1449-69
256. Cursiefen C, Colin J, Dana R, et al. Consensus statement on indications for antiangiogenic therapy in the management of corneal diseases associated with neovascularisation: outcome of an expert roundtable. Br J Ophthalmol 2012;96:3-9
257. Heier JS, Boyer D, Nguyen QD, et al. The 1-year results of CLEAR-IT 2, a phase 2 study of vascular endothelial growth factor trap-eye dosed asneeded after 12-week fixed dosing. Ophthalmology 2011;118:1098-106
258. Zuo L, Fan Y, Wang F, et al. A siRNA targeting vascular endothelial growth factor-A inhibiting experimental corneal neovascularization. Curr Eye Res 2010;35:375-84
259. Keskin U, Totan Y, Karadaǧ R, et al. Inhibitory effects of SU5416, a selective vascular endothelial growth factor receptor tyrosine kinase inhibitor, on experimental corneal neovascularization.Ophthalmic Res 2011;47:13-8
260. Chaoran Z, Zhirong L, Gezhi X. Combination of vascular endothelial growth factor receptor/platelet-derived growth factor receptor inhibition markedly improves the antiangiogenic efficacy for advanced stage mouse corneal neovascularization. Graefes Arch Clin Exp Ophthalmol 2011;249:1493-501
261. Hashizume H, Falcón BL, Kuroda T, et al. Complementary actions of inhibitors of angiopoietin-2 and VEGF on tumor angiogenesis and growth. Cancer Res 2010;70:2213-23
262. Al-Mahmood S, Colin S, Farhat N, et al. Potent in vivo antiangiogenic effects of GS-101 (5'-TATCCGGAGGGCTCGCCATGCTGCT-3'), an antisense oligonucleotide preventing the expression of insulin receptor substrate-1. J Pharmacol Exp Ther 2009;329:496-504
263. Cursiefen C, Bock F, Horn FK, et al. GS-101 antisense oligonucleotide eye drops inhibit corneal neovascularization: interim results of a randomized phase II trial. Ophthalmology 2009;116:1630-7